NCT04887870 2025-10-10Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent StudyMirati Therapeutics Inc.Phase 2/3 Completed52 enrolled
NCT03666143 2024-11-04A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid TumorsBeiGenePhase 1 Completed216 enrolled 20 charts
NCT03941873 2024-10-26A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerBeiGenePhase 1/2 Completed111 enrolled 22 charts
NCT04472650 2024-10-26Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy AdultsBeiGenePhase 1 Completed26 enrolled 14 charts
NCT04518046 2024-06-05Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesMirati Therapeutics Inc.Phase 1 Completed22 enrolled
NCT04887194 2024-05-08PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of SubstratesMirati Therapeutics Inc.Phase 1 Completed40 enrolled
NCT02219711 2023-03-06Phase 1/1b Study of MGCD516 in Patients With Advanced CancerMirati Therapeutics Inc.Phase 1 Completed193 enrolled